Biblio
Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS/ERK signalling pathway. Clin Transl Med. 2023;13(11):e1475.
SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer. Nat Commun. 2023;14(1):7572.
Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1/FOXO pathway. Cancer Lett. 2023:216470.
SETD2 deficiency promotes renal fibrosis through the TGF-β/Smad signalling pathway in the absence of VHL. Clin Transl Med. 2023;13(11):e1468.